Figure 6.

Comparison of regressing and relapsing tumor microenvironment. 10⁵ TC-1 cells were implanted on the back of C57BL/6 mice. When tumors were visible, mice were treated with two administrations of a combination of KISIMA vaccine and STING agonist at one-week interval. (A) Vaccination schedule and tumor growth. (B) Expression level of H2-Kb, H2-Db on CD45-tumor infiltrating cells and frequency of MHC-II^hi among CD11b+ cells. (C) One (regressing) or four (relapsing) tumors. One (regressing) or four (relapsing) weeks post the last treatment, mice were sacrificed, tumor harvested, and tumor microenvironment was analyzed by FACS staining. Proportion of different cell populations among CD45+ tumor-infiltrating cells is shown; every circle represents 1% of the CD45+ population (see Figure S11 for gating strategy). (D) Sequence of HPV-E7 CD8 epitope expressed by implanted and relapsing tumors. (B–D) One representative of two experiments is shown (n ≥5/group/replicate), Mann–Whitney test, **p < 0.01.